Contact information for researchers and applicants

Vrouw met headset

Grant Management Team

If you have any questions, please contact our Grant Management Team. They are happy to help you with the administrational procedures regarding your grant application or ongoing research project. They can also refer you to one of our Programme Coordinators who supervise our research projects by research theme.

T: +31 20 - 570 04 50
bestedingen@kwf.nl 

Programme Coordinator Team

Dr. Nora Liu - Programme coordinator Basic Research 

Scientific research aimed at obtaining insight into the origin and progression of cancer, its (psychosocial) effects, as well as basic principles of prevention and treatment of cancer and relevant technological developments. Basic research does not directly focus on the possible application of this knowledge.  

Dr. Gitta Buskermolen - Programme coordinator Basic Research 

Scientific research aimed at obtaining insight into the origin and progression of cancer, its (psychosocial) effects, as well as basic principles of prevention and treatment of cancer and relevant technological developments. Basic research does not directly focus on the possible application of this knowledge.  

Dr. Marion Scharpfenecker - Programme coordinator Biomarkers

Biomarkers are characteristics that are objectively measured and evaluated as an indicator for cancer risk, the presence of a specific cancer or recurrent cancer, the stage or severity of a specific cancer, and how well the patient responds to therapeutic intervention(s).  

Dr. Maud Plantinga - Programme coordinator Biomarkers

Biomarkers are characteristics that are objectively measured and evaluated as an indicator for cancer risk, the presence of a specific cancer or recurrent cancer, the stage or severity of a specific cancer, and how well the patient responds to therapeutic intervention(s).

Dr. Sigrid Oomen - Programme coordinator Interventive Devices 

Treatment instruments to prevent or treat local-regional sites of cancer or precancerous lesions. The modalities may be delivered non-invasively (e.g. radiation therapy), minimally invasively (e.g.cryoablation, hyperthermia) or by open surgery (invasive).

Dr. Bas Pouw - Programme coordinator Imaging

Scientific research into imaging includes various types of techniques to obtain detailed pictures of areas inside the body, such as magnetic fields (MRI), X-rays (CT), ultrasound (echography) and radioactive substances (PET) for functional imaging. Imaging is used to detect early stage cancer, diagnose disease, plan treatment or assess therapeutic response.

Dr. Willeke la Fontaine - Ros - Programme coordinator Immunotherapy

Immunotherapy is a cancer treatment that helps the patient’s own immune system to recognize and destroy cancer. Examples are monoclonal antibodies (drugs that counteract immune suppression or mark cancer cells for destruction), cytokines (small proteins that regulate immune responses) and therapeutic vaccines.

Drs. Janneke van Doorn - Programma Coordinator Lifestyle & Exposure

This portfolio is defined by the influence of behaviour or (unwanted) exposure to exogenous factors on the development, the recurrence, the aggravation or the prevention of cancer and/or the development, the aggravation or the prevention of side effects from cancer (treatment). 

Dr. Eveline Noteboom - Programme coordinator Implementation

Research on methods to facilitate the implementation of concrete applications (with demonstrable added value compared to the current practice) into oncology policy and practice at national level. Implementation focuses on the actions of healthcare professionals and other stakeholders as a key variable in the sustainable implementation of evidence-based interventions.

Dr. Delphi Coppens - Programme coordinator Cell & Gene Therapy

Cell therapy is the transfer of living cells into a patient to treat cancer. It usually involves immune cells that have been modified to recognize and destroy cancer cells (e.g. dendritic cell vaccination or CAR T-cell therapy). Gene therapy is transfering genetic material into a patient and alterating the genetic code to treat cancer.

Dr. Linda Schoo - Programme Coordinator Quality of Care

Scientific studies aimed at providing the most appropriate care to all cancer patients in all regions through optimal availability of therapies and the correct use thereof. Patient-driven indicators and real world evidence are included in the shared decision making process where possible. The results contribute to the best fitted treatment strategy for each individual patient, to providing (health) care providers with the most recent insights, and to transparency about the quality of the care offered.

Drs. Mai Tran - Programme coordinator Infrastructure

Infrastructural initiatives provide services, resources and networks to support cancer research. These initiatives enable the research community to address specific research questions and thereby help accelerate and/or optimise the exploitation of results to the patients and public. 

Drs. Janneke van Doorn - Programme coordinator Quality of Life 

Quality of life is among other things influenced by the psychological, social and societal impact of the disease. This includes topics such as anxiety, depression, relationship problems, return to work, the degree of independence and personal beliefs. Even when the disease can no longer be cured.

Programme coordinator Agents  - Vacancy

Drugs or biologicals used to prevent or inhibit the proliferation of cancerous cells. Examples of agents are small molecules, therapeutic enzymes and hormones.

Programme coordinator Clinical trials (focus: immunotherapy) - vacancy

Clinical trials are research studies performed in people to find out if new treatments are safe and effective. KWF supports researchers in conducting their trials and disseminating and implementing their results.